AUA 2025 Kidney Cancer

Viewing 1-11 of 11 articles

AUA 2025: Active Surveillance for Clinical Stage T1b Renal Masses in a Large Statewide Collaborative.

AUA 2025: Robotic-Assisted Partial Nephrectomy in Augmented Reality: Reliability of a Neural Network Training Methodology for Automated Renal Parenchyma Recognition (UROCCR 112)

AUA 2025: Renal Mass Biopsy for Small Renal Masses: A Single Center 20-Year Experience

AUA 2025: Comparative Assessment of Combination of Tyrosine Kinase Inhibitors with Immunotherapy Versus Dual Combination Immunotherapy as First-Line Treatment for Patients with Advanced RCC: A Multicenter Study Using the TOURS Database

AUA 2025: Comparison of Clinical Outcomes Between Cabozantinib + Nivolumab and Lenvatinib + Pembrolizumab in Advanced RCC

AUA 2025: Prognostic Impact of the Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab Combination Therapy

AUA 2025: Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitor Combination Therapies for Metastatic Renal Cell Carcinoma with Primary Kidney Tumors

AUA 2025: Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma

AUA 2025: Impact of Timing of Recurrence on Survival Outcomes: Implications for Postoperative Management in a KEYNOTE-564 Population

AUA 2025: Primary Resistance to Nivolumab plus Ipilimumab Therapy Affects Second-Line Treatment Outcomes in Patients with mRCC

AUA 2025: Cost-Effectiveness Analysis of 89Zr-Girentuximab PET—CT (TLX250) to Guide Management of Small Renal Masses